Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Prudential PLC (PUK) Price & Performance

Gilead Sciences, Inc.Trade
Prudential PLCTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Prudential PLC — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Prudential PLC trades at $27.67 (market cap $34.98B). The key difference: Gilead Sciences, Inc. is far larger — about 4.7× Prudential PLC's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.

GILDPUK
Market Cap
$164.99B$34.98B
Sector
HealthFinancials
52-Week High
$155.80$33.61
52-Week Low
$110.56$24.98
Enterprise Value
$188.06B$36.41B
Dividend Yield
2.47%1.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

No Aura AI signal available yet.

Prudential PLC

Prudential Financial (PUK) trades at $28.28, up 1.43% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with Q2 2025 and Q4 2025 earnings beats, robust 14.52% net income margin, and improving cash flow trends. Recent news highlights China regulatory concerns impacting Asian-focused insurers, though Prudential reported solid Q2 2026 results with $985 million net income.

The stock presents value characteristics with a low P/E of 9.21, supported by analyst consensus leaning bullish (50% buy ratings). Key risks include China regulatory exposure and competitive pressures in Asian markets. Upside potential exists if the company successfully executes its capital-light strategy and navigates geopolitical challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Prudential PLC

Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.

Read more on PUK